Pharvaris N.V. Overview
Pro stress-test →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks, with its lead candidate deucrictibant in pivotal Phase 3 trials.
Strategic Profile
Pro stress-test →RAPIDe-3 met its primary and all secondary endpoints with median onset of symptom relief of 1.28 hours, positioning deucrictibant competitively as an oral alternative to injectable treatments. Cash and cash equivalents were €247 million on March 31, 2026, excluding a subsequent $132.3 million underwritten offering that is expected to extend the cash runway into 2028.
Competitive Landscape
Pro stress-test →Pharvaris competes in the rare disease angioedema market against other bradykinin pathway modulators and C1-inhibitor replacement therapies. Key comparable companies include Xenon Pharmaceuticals, KalVista Pharmaceuticals, and other rare disease-focused biotechs. Pharvaris' differentiation lies in its oral formulation for both on-demand and prophylactic use, contrasting with existing injectable options.
Industry Context
Pharvaris N.V. operates in Rare Disease Biopharmaceuticals.
Key facts
Founded: 2015 · Headquarters: Zug, Switzerland · Employees: 129 · Market cap: $2.07B